|1.||Trusinskis, Karlis: 3 articles (06/2015 - 03/2013)|
|2.||Juhnevica, Dace: 3 articles (06/2015 - 03/2013)|
|3.||Erglis, Andrejs: 3 articles (06/2015 - 03/2013)|
|4.||Strenge, Karlis: 3 articles (06/2015 - 03/2013)|
|5.||Schrader, Christoph: 2 articles (07/2010 - 05/2004)|
|6.||Dengler, Reinhard: 2 articles (07/2010 - 05/2004)|
|7.||David, A: 2 articles (01/2007 - 01/2000)|
|8.||Levin, L Scott: 1 article (11/2015)|
|9.||Nicoli, Fabio: 1 article (11/2015)|
|10.||Li, Qi: 1 article (11/2015)|
|1.||Schizophrenia (Dementia Praecox)
08/01/1983 - "Local reactions at injection sites have limited the use of depot fluspirilene, an otherwise effective treatment for chronic schizophrenia. "
12/01/1970 - "A controlled study of fluspirilene in chronic schizophrenia."
01/01/2007 - "To review the effects of depot fluspirilene versus placebo, oral anti-psychotics and other depot antipsychotic preparations for people with schizophrenia in terms of clinical, social and economic outcomes. "
01/01/2007 - "Depot fluspirilene for schizophrenia."
01/01/2000 - "To assess the effects of depot fluspirilene versus placebo, oral anti-psychotics and other depot antipsychotic preparations for people with schizophrenia in terms of clinical, social and economic outcomes. "
03/01/2013 - "The purpose of this study was to evaluate plaque characteristics of culprit and non-culprit lesions in ST-elevation myocardial infarction (STEMI) patients at the index procedure and 10 months later using iMap intravascular ultrasound (IVUS). "
03/01/2013 - "iMap intravascular ultrasound evaluation of culprit and non-culprit lesions in patients with ST-elevation myocardial infarction."
02/01/2015 - "Coronary atheroma composition and its association with segmental endothelial dysfunction in non-ST segment elevation myocardial infarction: novel insights with radiofrequency (iMAP) intravascular ultrasonography."
03/01/2014 - "The purpose of the study was to evaluate associations between iMap intravascular ultrasound tissue characterization of culprit and nonculprit lesions in infarct-related artery and plasma biomarkers during ST segment elevation myocardial infarction (STEMI) and at 10-month follow-up. "
06/01/2015 - "The purpose of this study was to compare plaque characteristics of native coronary atherosclerosis and in-stent neointima ten months after ST elevation myocardial infarction (STEMI) using iMap intravascular ultrasound (IVUS). "
|3.||Anxiety Disorders (Anxiety Disorder)
10/01/1995 - "The main finding of the study is that there is a significant correlation between initial response after 2 weeks of test therapy and therapeutic success after 6 weeks in fluspirilene treatment of generalized anxiety disorders. "
02/01/1995 - "The present study was designed to investigate the interaction between therapeutic effects and side-effects in fluspirilene treatment of generalised anxiety disorders (GAD). "
10/01/1995 - "1. The present double-blind study was designed to determine under three different conditions (0.5 mg, 1.0 mg, 1.5 mg per week) whether response or non-response within a two-week test-therapy predicts clinical outcome after 6 weeks of fluspirilene treatment in generalized anxiety disorders. "
10/01/1995 - "Test therapy in the treatment of generalized anxiety disorders with low dose fluspirilene."
02/01/1995 - "[Interaction of therapeutic effects and side effects in drug therapy of generalized anxiety disorders with low dosage fluspirilene]."
|4.||Movement Disorders (Movement Disorder)
11/01/1990 - "The results of this study do not indicate an increase in tardive dyskinesia for patients with a mean duration of treatment with fluspirilene 1.5 mg/week of 18 months."
11/01/1990 - "In recent years concern has been frequently expressed that a long-term treatment with fluspirilene 1.5 mg/week might induce tardive dyskinesia, yet there are no empirical data from controlled studies available. "
09/01/1989 - "It is concluded that the application of fluspirilene would seem to be safe if the drug is administered in the recommended way, but that there is a risk of tardive dyskinesias in the case of higher doses, longer duration of use, or pre-existing cerebral lesions (as manifested by two patients included in this survey)."
05/01/2004 - "We describe a patient with fluspirilene-induced tardive dyskinesia of the choreiform oro-facial-laryngeal type resistant to various conservative approaches for 7 years who underwent deep brain stimulation of the internal pallidal globe. "
11/01/1990 - "In the fluspirilene group a positive correlation of age and psychotropic comedication with the total scores of the AIMS and the akathisia scale could be found, but there was no correlation between duration or continuity of treatment with fluspirilene and symptoms of tardive dyskinesia. "
02/01/2015 - "Furthermore, fluspirilene could also serve as a structurally-novel lead molecule for the development of more potent, small-molecule p53-MDM2 inhibitors against several types of cancer. "
02/01/2015 - "It is noteworthy here that fluspirilene has a long history of safe human use, thus presenting immediate clinical potential as a cancer therapeutic. "
02/01/2015 - "The experimental testing of fluspirilene showed significant growth inhibition of human colon tumor cells in a p53-dependent manner. "
01/01/2015 - "Our results showed that oral fluspirilene treatment significantly inhibited tumor growth. "
01/01/2015 - "In Silico Identification and In Vitro and In Vivo Validation of Anti-Psychotic Drug Fluspirilene as a Potential CDK2 Inhibitor and a Candidate Anti-Cancer Drug."
|2.||fluphenazine depot (modecate)
|4.||Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)
|5.||Biological Markers (Surrogate Marker)
|9.||Antipsychotic Agents (Antipsychotics)
|10.||GTP Phosphohydrolases (GTPases)
|4.||Deep Brain Stimulation